Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 01)
Cyclobenzaprine Hydrochloride
Product Images NDC 50090-3253
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Cyclobenzaprine Hydrochloride (NDC 50090-3253). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 02)
This is a chart displaying the percentage of patients experiencing certain side effects from two different doses of the drug Cyclobenzaprine HCI Tablets and a placebo. The side effects are drowsiness, dry mouth, fatigue, and headache. The 5mg dosage had a total of 464 patients, and the 10mg dosage had a total of 249 patients. The placebo had a total of 469 patients.*
Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 03)
This text appears to be presenting data on the side effects associated with a medication called Cyclobenzaprine HCI Tablets, 10mg based on clinical studies and surveillance programs. It indicates that drowsiness is the most commonly reported side effect at 39%, followed by dry mouth at 2% and dizziness at 1%. The percentages in the surveillance program category are not clear as to what they represent.*
Label Image (Lbl500903253)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
